Disease Introduction
Heart failure, commonly known as angina, is a clinical syndrome characterized by a decline in the heart's pumping function, resulting in an inability to meet the body's blood supply needs. Typical symptoms include shortness of breath after exertion, nocturnal awakening with dyspnea, lower extremity edema, and fatigue. The general principle of treatment is to start medication as early and in a standardized manner to reduce the burden on the heart, based on the "new quadruple therapy" of ARNI (sacubitril/valsartan), beta-blockers, aldosterone receptor antagonists, and SGLT2 inhibitors. For advanced refractory heart failure, pacing resynchronization, ventricular assist devices (artificial hearts), or heart transplantation may also be considered.
Cutting-edge high-precision diagnostic and treatment technologies
- The new quadruple therapy has become widespread : ARNI + β-blocker + aldosterone receptor antagonist + SGLT2 inhibitor has become the standard "new quadruple therapy" for heart failure with reduced ejection fraction (HFrEF). The real-world usage rate of this combination in China has increased from 10.08% in 2020 to 74.77% in 2025.
- SGLT2 inhibitors for HFpEF : The Chinese Expert Consensus on the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction (2025 Edition) strongly recommends the use of SGLT2 inhibitors (dapagliflozin/empagliflozin) for all HFpEF patients, which can reduce the risk of hospitalization and death by approximately 20%.
- Domestic artificial heart : The domestically produced third-generation fully magnetically levitated left ventricular assist device, Corheart6, has a diameter of only 34mm and weighs about 90g, making it the smallest and lightest commercially available artificial heart in the world; among 76 implanted patients at Fuwai Hospital, the 1/2/3-year survival rate reached 91.0%, and 4 patients were successfully weaned off the pump.
- Pediatric Dual-Heart Assist : In March 2025, Wuhan Union Hospital implanted a self-developed pediatric magnetic levitation biventricular assist device (pump diameter approximately 2.9cm) into a 7-year-old child with dilated cardiomyopathy. This device is the smallest and lightest pediatric dual-heart assist device in the world.
- His-Purkinje system pacing : The 2025 European Society of Cardiology consensus on conduction system pacing (CSP) proposes that CSP can be used as an alternative to traditional biventricular resynchronization therapy (BiV-CRT) for patients with LVEF≤35%, left bundle branch block, QRS≥130ms, and symptomatic heart failure that is refractory to medication.
